ASSC Executive

Professor H. Peter Soyer

Chair in Dermatology

Director, Dermatology Research Centre, The University of Queensland Diamantina Institute
Director, Dermatology Department, Princess Alexandra Hospital

Professor H. Peter Soyer has a dual academic/clinical role as the inaugural Chair and Director of the Dermatology Research Centre, The University of Queensland (UQ) Diamantina Institute, at the Translational Research Institute, and as Director of the Dermatology Department at the Princess Alexandra Hospital. Professor Soyer, an academic dermatologist from Austria, is a world leader in the field of dermatology with particular expertise in dermatooncology and dermatologic imaging. His research group’s main focus is skin cancer (both melanoma and keratinocyte skin cancer) and he is co-inventor in patents for novel skin delivery platforms and microbiospy sampling devices. He has an extensive publication record with over 500 publications (>120 publications in the last 5 years), over 650 citations a year and a Hirsch index of 50 (Researcher ID).

He initiated establishment (2016) and is Co-leader of the Australian Skin and Skin Cancer (ASSC) Research Centre, a joint venture between UQ and QIMR Berghofer Medical Research Institute. He was Co-President of the 9th World Congress of Melanoma, Brisbane, Australia, 2017. He is lead investigator of the Centre of Research Excellence for the Study of Naevi funded by the Australian Government National Health and Medical Research Council (NHMRC), a Queensland Genomics Health Alliance Demonstration Project ‘A Genomics Approach for Screening of Patients at High Risk of Melanoma’, and a UQ Faculty of Medicine Health Outcome Program ‘3D QMelanoma – Targeted Early Detection of Melanoma Utilising a 3D Teledermatology Network’. He was recently awarded a Medical Research Future Fund (MRFF) Next Generation Clinical Researchers Program Practitioner Fellowship (2018-2022).


Professor David Whiteman

B Med Sc, MBBS(Hons), PhD, FAFPHM
Deputy Director
Head, Cancer Control Laboratory
Coordinator, Melanoma and Skin Cancer Research Centre
QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

Professor David Whiteman is a medical epidemiologist with a special interest in the causes, control and prevention of cancer. He received his medical degree from the University of Queensland in 1991, and his PhD in cancer epidemiology in 1997.

He was awarded a Nuffield Medical Research Fellowship to undertake post-doctoral training at the University of Oxford in cancer epidemiology. He returned to Brisbane in 2000, and now leads a large program of cancer research comprising national and international studies of melanoma and other cancers.

Professor Whiteman has an international reputation for research into melanoma and skin cancer. In addition to his research activities, he is a:

  • Fellow of the Australian Academy of Health and Medical Sciences
  • Fellow of the Australasian Faculty of Public Health Medicine
  • Honorary Fellow of the Skin Cancer College of Australasia
  • Member of the Academy of the National Health and Medical Research Council of Australia (NHMRC).

He previously chaired the Fellowships committee of the International Agency for Research on Cancer and served as a Member of Council of NHMRC, the NHMRC National Asbestos Research Working Group and the NHMRC Strategic Research Development Committee. In 2006, he was awarded a Fulbright Senior Scholarship to visit cancer researchers in the United States.

Professor Kiarash Khosrotehrani

Experimental Dermatology Group Leader
The University of Queensland Centre for Clinical Research
The University of Queensland Diamantina Institute

Affiliate Associate Professor
SOMSouthern – Medicine – Princess Alexandra Hospital
Faculty of Medicine and Biomedical Sciences

Professor Khosrotehrani is a clinical scientist interested in skin biology, regenerative medicine and skin cancer.

He was recently appointed at the University of Queensland Centre for Clinical Research (UQCCR) and the newly established Translational Research Institute in Brisbane, Australia. Dr Khosrotehrani obtained his MD from the Cochin-Port Royal School of Medicine at René Descartes University, Paris, France, specialized in Dermatology and a fellow of the Australasian College of Dermatologists.

He is also a former graduate of the Ecole Normale Supérieure and the Institut Pasteur of Paris (Université Paris VI, Pierre et Marie Curie) where he obtained a PhD in Physiology and Physiopathology. During his post-doctoral training at Tufts-New England Medical Center, Boston, USA, Dr. Khosrotehrani helped establish the contribution of pregnancy-associated stem cells to tissue repair by demonstrating their multipotent capacity with a specific potency towards the endothelial lineage. The originality of this work was recently acknowledged by the NHMRC through an achievement award (2011) and he is currently an NHMRC Career Development Fellow.

The main focus of his laboratory, the Experimental Dermatology Group, is on mesenchymal-epidermal interactions in stem cell maintenance and cancer. His research has broad applications in skin wound healing, regenerative medicine and cancer initiation and progression.

Professor Nicholas Hayward

National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow
Head, Oncogenomics Laboratory, QIMR Berghofer Medical Research Institute

Professor Nicholas Hayward obtained his PhD from the University of Queensland in 1983 and is currently Head of the Oncogenomics Laboratory and Deputy Coordinator of the Cancer Program at the QIMR Berghofer Medical Research Institute. He has studied the molecular genetics of melanoma for more than 30 years and is a foundation member of the International Melanoma Genetics Consortium (GenoMEL) and the Society for Melanoma Research.

Professor Hayward’s work spans molecular epidemiology, genetics, genomics, cell biology and mouse models of melanoma. He played key roles in the identification of CDK4, MITF, POT1, ACD and TERF2IP as familial melanoma susceptibility genes and has contributed significantly to several genome-wide association studies for melanoma and the associated phenotypic traits of pigmentation and naevi.

Through his extensive research collaborations Professor Hayward has contributed to the understanding of key somatic mutations that drive melanocyte neoplasia, including the seminal findings of BRAF mutations in naevi, and MAP3K5, MAP3K9, RASA2 and RAC1 mutations in melanoma. He is currently a principal investigator of the Australian Melanoma Genome Project – an endeavour that aims to characterise the genomic landscape of somatic mutations and chromosomal aberrations in more than 500 melanomas.